CVMarkets Broker Mentions The Best Stocks to Invest $3,000 in Right Now

London, England, 2 June 2021, ZEXPRWIRE, Investors have learned a valuable lesson in patience over the last 15 months. Despite the coronavirus collapse slashing 34% off the benchmark S&P 500 in less than five weeks, the widely followed index recovered all of its losses in less than five months and soared to new all-time highs.

Even though the S&P 500 is on the verge of breaking yet another record high, the value may still be found.

CVMarkets broker elaborates that the following are some of the finest stocks to invest in right now if you have $3,000 that won’t be needed to cover emergencies or pay bills, and you have a long-term perspective.

• ALPHABET (GOOG/GOOGL)

You don’t have to flip every stone over in search of a diamond. Brand-name firms, such as Alphabet (NASDAQ: GOOGL), are sometimes the finest stocks to purchase (NASDAQ: GOOG). Google, an online search engine, and YouTube, a video-streaming platform, are among its subsidiaries.

Google, Alphabet’s search engine, is the company’s basic sector. According to statistics from Global Stats, Google has maintained a worldwide search share of between 91 percent and 93 percent for the previous couple of years. With such a monopoly, it’s no surprise that marketers are prepared to pay a high price for advertising space. Nevertheless, Alphabet’s traffic acquisition expenses should fall over time, allowing for moderate profit expansion.

The company’s supplementary operations, on the other hand, are as exciting. For example, YouTube is one of the top three most-visited social media sites globally, with an annual revenue run-rate of $24 billion. Meanwhile, Google Cloud’s cloud infrastructure sector expanded 46 percent year over year in the first quarter. As a result, cloud margins can easily outperform ad margins and will undoubtedly be the key to Alphabet increasing its operating cash flow between 2020 and 2024.

• JUSHI HOLDINGS (JUSHF)

For patient investors, cannabis should be one of the top moneymaking phenomena of the decade. Though there are many high-growth marijuana stocks to select from, Jushi Holdings (OTC: JUSHF), a multistate operator (MSO) in the United States, meets all the requirements.

Even though Jushi is a tiny fry compared to several major MSOs, it has sensibly approached its expansion. Three states are receiving the majority of the company’s attention: Pennsylvania, Illinois, and Virginia. All three states have restrictions on how dispensary licenses are distributed. For example, retail license issuance is capped in Pennsylvania and Illinois, but Virginia allocates licenses depending on the jurisdiction. The key is that Jushi has entered areas where it can grow its brand and garner fans without being bullied by larger MSOs. Jushi is also confident in its ability to acquire purchases with its cash. As a result, it’s been strengthening its footprint in Pennsylvania and Virginia, as well as experimenting in California, the world’s largest marijuana market, by yearly sales.

Jushi has a realistic chance of increasing its yearly sales from less than $81 million in 2020 to more than $600 million by 2024.

• EXELIXIS (EXEL)

The majority of biotech stocks are losing money and are expecting to produce the next blockbuster medicine. Exelixis (NASDAQ: EXEL) isn’t like other biotech equities, thankfully. It’s profitable, and Cabometyx, the company’s primary cancer medicine, appears to be on track to exceed $1 billion in annual sales by 2022.

Cabometyx is licensed to treat RCC in the first and second lines and advanced hepatocellular carcinoma. Cabometyx has a billion-dollar potential based on these indications alone.

Exelixis, on the other hand, isn’t finished with its definitive therapy. Cabometyx is also being investigated in more than a half-dozen other cancer studies. Earlier this year, the Food and Drug Administration approved the combination of Cabometyx and Bristol Myers Squibb’s cancer immunotherapy Opdivo for first-line RCC based on the results of one such trial. In addition, Cabometyx has the potential for double-digit yearly growth due to factors such as label extension, length of use, and pricing power.

Exelixis’ primary medicine is also a cash cow and something investors should be aware of. The firm had nearly $1.6 billion in cash and cash equivalents at the end of March, almost 20% of its current market valuation. This money will help Exelixis re-ignite its research engine, and it may also allow the business to go shopping at some time in the future.

• EVERQUOTE (EVER)

Consider investing some of your $3,000 in EverQuote, an online insurance marketplace, if you didn’t get enough small-cap growth activity with Jushi (NASDAQ: EVER).

Insurance is as fun as watching paint dry. I understand it. Every time a GEICO advertising plays on the radio, I want to stab sharp things into my ears. However, the way insurance products are sold to customers is changing, and EverQuote is in the market’s fastest-growing segment. The average annual increase in digital insurance marketing expenditure is predicted to be 16 percent over the next four years.

The internet insurance marketplace at EverQuote serves two purposes. It simplifies and clarifies pricing rules for customers, and it lets insurers use their advertising expenditures more efficiently. Insurers are receiving more bang for their buck using EverQuote’s customized platform rather than putting that money into a broad audience of individuals.

Best of all, EverQuote isn’t content with simply being a source for vehicle insurance quotes. Home, rental, life, and health insurance are among the new sectors it has entered. These verticals have grown at a far higher rate than vehicle insurance revenue. As a result, over the next four years, Wall Street believes EverQuote has the potential to treble its income.

Disclaimer: Our content is intended to be used for informational purposes only. It is very important to do your own research before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on this article and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

Source: Bitteks